# US 2012/0253074 A1 · Process for the preparation of o-desmethyl-venlafaxine and salts thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0253074 A1
- Document ID: US20120253074A1
- Status: Published application
- Kind: A1
- Application number: 13/515,871
- Filed: 2009-12-16
- Published: 2012-10-04
- Earliest claimed: 2009-12-16
- Assignees: Pharmathen S.A.
- Inventors: Theoharis V. Koftis; Ioanna Georgopoulou; Alexandros Strongilos; Fotini Liepouri; Theodoros Panagiotidis; Alexandra Lithadioti
- Web page: https://patentgrep.com/patent/US20120253074A1

## CPC

- C07C 215/64: with rings other than six-membered aromatic rings being part of the carbon skeleton
- C07C 55/06: Oxalic acid
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07C 2601/14: The ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to a novel process for the preparation of O-desmethyl venlafaxine (ODV) and the pharmaceutically acceptable salts thereof, wherein it comprises (i) provision of spiro-venlafaxine compound as intermediate; (ii) conversion of spiro-venlafaxine intermediate into ODV free base in a one-pot process; and (iii) optionally conversion ODV free base into pharmaceutically acceptable salts. The present invention further relates to novel processes for the preparation of crystalline salts of OD V-succinate and ODV-oxalate.

## Claims

### Claim 1

A process for the preparation of O-desmethyl Venlafaxine or pharmaceutically acceptable salts or derivatives thereof, which comprises:
(a) Provision of compound of (5RS)-5-(4-methoxyphenyl)-3-methyl-1-oxa-3-azaspiro[5,5] undecane, namely the spiro-venlafaxine;
(b) conversion of spiro-venlafaxine into spiro-venlafaxine hydrochloride salt and isolation of said salt in pure form;
(c) obtaining O-desmethyl Venlafaxine free base in a one-pot process using spiro-venlafaxine hydrochloride salt as starting material, wherein said one-pot process of step is performed by first O-demethylating of the spiro-venlafaxne hydrochloride obtained from step (b) and subsequently treating the reaction mass with paraformaldehyde, formic acid and water at elevated temperature, preferably from about 105 to about 110° C., to obtain O-desmethyl Venlafaxine free base.

### Claim 2 (depends on 1)

The process according to claim 1, wherein it further comprises
(d) conversion of O-desmethyl Venlafaxine free base into a pharmaceutically acceptable acid additional salt thereof;
(e) recrystallization of O-desmethyl Venlafaxine salt to obtain crystalline O-desmethyl Venlafaxine salt.

### Claim 3 (depends on 1)

The process according to claim 1, wherein the compound of (5RS)-5-(4-methoxyphenyl)-3-methyl-1 -oxa-3-azaspiro [5, 5] undecan, the Spiro -venlafaxine is obtained by hydrogenating (1RS)-1-[cyano-1-(methoxyphenyl) methyl] cyclohexanol followed by ring-closing the hydrogenation product.

### Claim 4 (depends on 4)

The process according to claim 4, wherein the ring-closing process is performed by mixing the aqueous solution of the hydrogenation product with paraformaldehyde and formic acid and heating said reaction mixture at moderate temperature, preferably about 55° C.

### Claim 5 (depends on 1)

The process according to claim 1, wherein the spiro-venlafaxne hydrochloride salt of step (b) is obtained by treating spiro-venlafaxine with an iso-propanol solution of hydrochloride followed by recrystallization in isopropanol.

### Claim 6 (depends on 1)

The process according to claim 1, wherein the O-desmethylating process of step (c) is carried out using alkane thiolate anion in the presence of high molecular weight polyol and alcoholic solvent.

### Claim 7 (depends on 2)

The process according to claim 2, wherein said O-desmethyl Venlafaxine free base is reacted with oxalic acid to form the oxalate salt of O-desmethyl Venlafaxine and said O-desmethyl Venlafaxine oxalate solid is re-crystallized using acetone/ethanol.

### Claim 8 (depends on 2)

A compound O-desmethyl Venlafaxine oxalate obtained according to claim 2, wherein said O-desmethyl Venlafaxine oxalate is in crystalline form.

### Claim 9 (depends on 8)

The compound of claim 8, characterized by a powder XRD pattern with peaks at about 15.2 and 26.7±0.2 degree 2-theta.

### Claim 10 (depends on 8)

The compound of claim 8, characterized by a powder XRD pattern with peaks at about 15.2 and 26.7±0.2 (degree 2-theta), and further characterized by two or more additional peaks selected from: about 5.3, 10.6, 11.9, 19.4, 22.3, 24.9 and 30.1±0.2 degree 2-theta.

### Claim 11 (depends on 8)

The compound of claim 8, characterized by a powder XRD pattern having peak locations as depicted in FIG. 1.
